Clinical Trial Update: Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating neoadjuvant mFOLFIRINOX with or without preoperative chemoradiotherapy in borderline resectable pancreatic cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Irinotecan (Irinotecan)
• Leucovorin (folinic acid)
• OXALIPLATIN (Oxaliplatin)

Snippet

Sponsor: Institut de Cancérologie de Lorraine | Conditions: Pancreatic Carcinoma | Phase 2 | Status: COMPLETED